Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Ovarian Cancer News

News
Assessing Risk Factors for Progression Among Patients With Advanced Ovarian Cancer After Response to First-line Platinum-Based Chemotherapy
05/31/2022

Ellen Kurek

Ellen Kurek
Multiple factors were associated with shorter time to next treatment or overall survival in a recent retrospective real-world analysis on patients with ovarian cancer.
Multiple factors were associated with shorter time to next treatment or overall survival in a recent retrospective real-world analysis on patients with ovarian cancer.
Multiple factors were associated...
05/31/2022
Journal of Clinical Pathways
News
Utilization of Genetic Testing Among Commercially Insured Patients With Ovarian Cancer
05/13/2022

Ellen Kurek

Ellen Kurek
Study findings reveal only 33.9% of commercially insured patients with ovarian cancer received germline BRCA testing, despite guideline recommendations.
Study findings reveal only 33.9% of commercially insured patients with ovarian cancer received germline BRCA testing, despite guideline recommendations.
Study findings reveal only 33.9%...
05/13/2022
Journal of Clinical Pathways

Advertisement

News
Efficacy of Oral Etoposide Among Patients With Recurrent or Refractory Epithelial Ovarian Cancer
05/10/2022

Ellen Kurek

Ellen Kurek
The administration of oral etoposide at a dose of 50 mg/m2 showed fairish oncologic outcomes with manageable toxicity among patients with recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
The administration of oral etoposide at a dose of 50 mg/m2 showed fairish oncologic outcomes with manageable toxicity among patients with recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
The administration of oral...
05/10/2022
Journal of Clinical Pathways
News
Real-World Use and Outcomes of Adjuvant Bevacizumab Therapy Prior to Regulatory Approval for Newly Diagnosed Ovarian Cancer
04/26/2022

Ellen Kurek

Ellen Kurek
A recent retrospective cohort study found that among patients with newly diagnosed ovarian cancer, real-world patterns of upfront bevacizumab use prior to FDA approval in 2018 differed significantly from trial data.
A recent retrospective cohort study found that among patients with newly diagnosed ovarian cancer, real-world patterns of upfront bevacizumab use prior to FDA approval in 2018 differed significantly from trial data.
A recent retrospective cohort...
04/26/2022
Journal of Clinical Pathways
News
Progression-Free Survival Associated With Olaparib With or Without Cediranib vs Platinum-Based Chemotherapy in Women With High-Grade Ovarian Cancer
04/08/2022

Ellen Kurek

Ellen Kurek
Study findings suggest that neither olaparib monotherapy or olaparib plus cediranib increased progression-free survival when compared with platinum-based chemotherapy in women with high-grade serous or endometroid ovarian cancer sensitive to...
Study findings suggest that neither olaparib monotherapy or olaparib plus cediranib increased progression-free survival when compared with platinum-based chemotherapy in women with high-grade serous or endometroid ovarian cancer sensitive to...
Study findings suggest that...
04/08/2022
Journal of Clinical Pathways

Advertisement

News
Experts Provide Algorithm for Use of Bevacizumab and PARP Inhibitors in Patients With Newly Diagnosed, Advanced Ovarian Cancer
04/07/2022

Ellen Kurek

Ellen Kurek
Avelumab and atezolizumab may have limited impact on the clinical outcome of patients with newly diagnosed ovarian carcinoma, according to recent study findings.
Avelumab and atezolizumab may have limited impact on the clinical outcome of patients with newly diagnosed ovarian carcinoma, according to recent study findings.
Avelumab and atezolizumab may...
04/07/2022
Journal of Clinical Pathways
News
Real-World Experience With Bevacizumab for Newly Diagnosed Ovarian Cancer
03/22/2022

Janelle Bradley

Janelle Bradley
Among patients with ovarian cancer who received first-line treatment with bevacizumab, clinical outcomes and tolerability are consistent in the real-world setting and clinical trials.
Among patients with ovarian cancer who received first-line treatment with bevacizumab, clinical outcomes and tolerability are consistent in the real-world setting and clinical trials.
Among patients with ovarian...
03/22/2022
Journal of Clinical Pathways
News
Qualitative Study Explores Olaparib Adherence Among Patients With Ovarian Cancer
03/10/2022

Marta Rybczynski

Marta Rybczynski
Findings from a qualitative study at the Mayo Clinic suggest that patients with ovarian cancer are willing to adhere to oral olaparib therapy long term.
Findings from a qualitative study at the Mayo Clinic suggest that patients with ovarian cancer are willing to adhere to oral olaparib therapy long term.
Findings from a qualitative...
03/10/2022
Journal of Clinical Pathways

Advertisement

News
Disease Progression After Olaparib Maintenance Prognosticates Poor Response to Subsequent Platinum-Based Chemotherapy in Ovarian Cancer
03/01/2022

Marta Rybczynski

Marta Rybczynski
Patients with platinum-sensitive, recurrent ovarian cancer whose disease progressed following olaparib maintenance experienced poor response to subsequent platinum-based chemotherapy, according to a recent study.
Patients with platinum-sensitive, recurrent ovarian cancer whose disease progressed following olaparib maintenance experienced poor response to subsequent platinum-based chemotherapy, according to a recent study.
Patients with...
03/01/2022
Journal of Clinical Pathways
News
Interventions Improve Symptom Controllability Among Patients With Recurrent Ovarian Cancers
02/24/2022
Marta Rybczynski
Study findings revealed the web-based WRITE Symptoms interventions significantly improved symptom controllability for patients with ovarian cancer, regardless of delivery method.
Study findings revealed the web-based WRITE Symptoms interventions significantly improved symptom controllability for patients with ovarian cancer, regardless of delivery method.
Study findings revealed the...
02/24/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use